Sandi John Demby, Levy Joshua I, Tapela Kesego, Zeller Mark, Yeboah Joshua Afari, Saka Daniel Frimpong, Grant Donald S, Awandare Gordon A, Quashie Peter K, Andersen Kristian G, Paemka Lily
West African Centre for Cell Biology of Infectious Pathogens (WACCBIP), College of Basic and Applied Sciences, University of Ghana, Accra, Ghana.
Department of Biochemistry, Cell and Molecular Biology (BCMB), School of Biological Sciences, College of Basic and Applied Sciences, University of Ghana, Accra, Ghana.
J Immunol Res. 2024 Feb 12;2024:6668017. doi: 10.1155/2024/6668017. eCollection 2024.
The immunological signatures driving the severity of coronavirus disease 19 (COVID-19) in Ghanaians remain poorly understood. We performed bulk transcriptome sequencing of nasopharyngeal samples from severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)-infected Ghanaians with mild and severe COVID-19, as well as healthy controls to characterize immune signatures at the primary SARS-CoV-2 infection site and identify drivers of disease severity. Generally, a heightened antiviral response was observed in SARS-CoV-2-infected Ghanaians compared with uninfected controls. COVID-19 severity was associated with immune suppression, overexpression of proinflammatory cytokines, including , , , and , and activation of pathways involved in keratinocyte proliferation. was among the differentially regulated interferon-stimulated genes in our mild and severe disease cohorts, suggesting that it may play a critical role in SARS-CoV-2 pathogenesis. By comparing our data with a publicly available dataset from a non-African (Indians) (GSE166530), an elevated expression of antiviral response-related genes was noted in COVID-19-infected Ghanaians. Overall, the study describes immune signatures driving COVID-19 severity in Ghanaians and identifies immune drivers that could serve as potential prognostic markers for future outbreaks or pandemics. It further provides important preliminary evidence suggesting differences in antiviral response at the upper respiratory interface in sub-Saharan Africans (Ghanaians) and non-Africans, which could be contributing to the differences in disease outcomes. Further studies using larger datasets from different populations will expand on these findings.
在加纳人中,驱动新型冠状病毒肺炎(COVID-19)严重程度的免疫特征仍未得到充分了解。我们对感染严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的轻度和重度COVID-19加纳人以及健康对照的鼻咽样本进行了批量转录组测序,以表征原发性SARS-CoV-2感染部位的免疫特征,并确定疾病严重程度的驱动因素。总体而言,与未感染的对照相比,在感染SARS-CoV-2的加纳人中观察到抗病毒反应增强。COVID-19的严重程度与免疫抑制、促炎细胞因子(包括 、 、 和 )的过表达以及角质形成细胞增殖相关途径的激活有关。 在我们的轻度和重度疾病队列中是差异调节的干扰素刺激基因之一,这表明它可能在SARS-CoV-2发病机制中起关键作用。通过将我们的数据与来自非非洲人(印度人)的公开可用数据集(GSE166530)进行比较,在感染COVID-19的加纳人中发现抗病毒反应相关基因的表达升高。总体而言,该研究描述了驱动加纳人COVID-19严重程度的免疫特征,并确定了可作为未来疫情或大流行潜在预后标志物的免疫驱动因素。它进一步提供了重要的初步证据,表明撒哈拉以南非洲人(加纳人)和非非洲人在上呼吸道界面的抗病毒反应存在差异,这可能导致疾病结果的差异。使用来自不同人群的更大数据集的进一步研究将扩展这些发现。